ClinicalTrials.govrestricted
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitiv
ClinicalTrials.gov study NCT07071961. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ShareScore
24/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4